Skip to content 
Unravel the science behind the influence of tobacco, alcohol, and cannabis on our DNA. Dive into the impact of these substances on DNA methylation and learn how these lifestyle choices can modify gene activity, potentially affecting health outcomes.
Exploring the impact of medical cannabis on health-related quality of life, this review delves into the Arkell et al. study in JAMA Network Open. With a focus on chronic pain patients, the research points to significant improvements across various health domains. Particularly, CBD-dominant cannabis products show promising results. Discover the key findings, strengths, and weaknesses of this impactful study.
Researchers conducted a systematic review of studies investigating the use of cannabinoid-based medicines (CBMs) for chronic pain management and developed clinical practice guidelines based on the evidence. The review found that CBMs may provide benefits for chronic pain reduction, especially for neuropathic pain, and help with some co-occurring conditions. However, CBMs may cause some adverse events, and the optimal use of CBMs for chronic pain and co-occurring conditions is not clear. The guidelines provide practical recommendations for clinicians on patient education, assessment, dosing, administration routes, monitoring, and discontinuation of CBMs.
A phase I double-blind placebo-controlled clinical trial examined the effects of a 10:1 CBD/THC sublingual spray in improving glycemic control and lipid profiles in patients with Type II Diabetes. The study involved 50 patients, 25 of whom were given a 200 mg/20 mg CBD/Δ9-THC sublingual spray twice daily for eight weeks, while the other 25 were given a placebo. The study found that the active treatment arm showed significant improvements in various biomarkers related to cardiovascular health and glucose metabolism. The results suggest that adjunctive treatment with sublingual CBD/Δ9-THC can improve glycemic control and lipid profiles in patients with Type II Diabetes.